Clinical trial • Phase I • Neurology
AX-5006 for Parkinson's disease
Phase I trial of AX-5006 for Parkinson's disease. 84 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Parkinson's disease
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 01-09-2025
- First CTIS Authorization Date
- 27-10-2025
Trial design
Phase I trial across 1 site in Netherlands.
- Target Sample Size
- 84
Eligibility
Recruits 84 No vulnerable populations selected; no specific consent or assent procedures described in the record..
- Vulnerable Population
- No vulnerable populations selected; no specific consent or assent procedures described in the record.
Recruitment
- Planned Sample Size
- 84
- Recruitment Window Months
- 9
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 84
Netherlands
- Earliest CTIS Part Ii Submission Date
- 17-10-2025
- Latest Decision Or Authorization Date
- 05-03-2026
- Processing Time Days
- 139
- Number Of Sites
- 1
- Number Of Participants
- 84
Sites
- Site Name
- Centre for Human Drug Research
- Department Name
- Neurology
- Contact Person Name
- Philip Kremer
- Contact Person Email
- clintrials@chdr.nl
Sponsor
Primary sponsor
- Full Name
- Vertero Therapeutics Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- AX-5006
Related trials
Other published trials that may interest you.